Education
About Us
Working with TipRanks
Follow Us
Daily Stock Ratings & Price Targets
Analyst Performance
Any
Analyst Rating
Any
Upside / Downside
Any
Action
Any
Market Cap
Any
Analyst & Firm | Company | Price | Rating & Price Target | Upside / Downside | Success Rate | Average Return | Action | Date | Article |
|---|---|---|---|---|---|---|---|---|---|
 xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $54 | ― | 19.00% | Upgraded | ||||
 xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | HOLD $12 | ― | 1.30% | Reiterated | ||||
| xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | HOLD $510 | ― | 1.30% | Reiterated | ||||
| xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $205 | ― | 1.30% | Reiterated | ||||
| Fair Isaac | BUY $2,500 | ― | -0.10% | Reiterated | Fair Isaac's Strong Market Position and Strategic Buybacks Reinforce Buy Rating Amid Economic Uncertainty | |||
 | NuScale Power | BUY $20 | ― | -2.40% | Initiated | NuScale Power (SMR) Receives a New Rating from BTIG | |||
 xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $60 | ― | 15.90% | Reiterated | ||||
 xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $140 | ― | 1.90% | Reiterated | ||||
| Argenx Se | BUY $780 | ― | -10.00% | Reiterated | Analysts Offer Insights on Healthcare Companies: Gilead Sciences (NASDAQ: GILD), Argenx Se (NASDAQ: ARGX) and COMPASS Pathways (NASDAQ: CMPS) | |||
 | COMPASS Pathways | BUY $11 | ― | -4.50% | Reiterated | Analysts Offer Insights on Healthcare Companies: Gilead Sciences (NASDAQ: GILD), Argenx Se (NASDAQ: ARGX) and COMPASS Pathways (NASDAQ: CMPS) | |||
| xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $58 | ― | 14.30% | Reiterated | ||||
 xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $25 | ― | 1.10% | Reiterated | ||||
 xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | HOLD $375→$308 | ― | 12.00% | Reiterated | ||||
| xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $121→$105 | ― | 12.00% | Reiterated | ||||
| xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | HOLD $110→$98 | ― | 12.00% | Reiterated | ||||
 xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | HOLD $88→$72 | ― | 17.30% | Reiterated | ||||
 xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $39 | ― | 9.60% | Initiated | ||||
| xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $46→$38 | ― | 12.00% | Reiterated | ||||
| xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $28 | ― | 25.10% | Initiated | ||||
| xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | HOLD $330→$225 | ― | 1.40% | Reiterated | ||||
 | Gain Therapeutics | BUY $12 | ― | -9.80% | Reiterated | Scotiabank Keeps Their Buy Rating on Gain Therapeutics (GANX) | |||
 | Travere Therapeutics | BUY $32→$30 | ― | -7.60% | Reiterated | Scotiabank Remains a Buy on Travere Therapeutics (TVTX) | |||
| Zai Lab | BUY $55 | ― | -9.80% | Reiterated | Zai Lab (ZLAB) Gets a Buy from Scotiabank | |||
| xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | HOLD $100 | ― | 1.30% | Reiterated | ||||
 xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | HOLD $410→$380 | ― | 13.50% | Reiterated | ||||
| xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $22→$20 | ― | 6.60% | Reiterated | ||||
| xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | HOLD $14 | ― | 12.00% | Reiterated | ||||
 xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $86 | ― | 4.50% | Reiterated | ||||
| Axos Financial | BUY $88 | ― | -0.10% | Reiterated | Needham Remains a Buy on Axos Financial (AX) | |||
| xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | HOLD $166 | ― | 4.50% | Reiterated | ||||
 xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $1,100 | ― | 0.80% | Reiterated | ||||
| xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $140→$156 | ― | 19.00% | Reiterated | ||||
| xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $61→$59 | ― | 19.00% | Reiterated | ||||
 xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $260→$215 | ― | 4.50% | Reiterated | ||||
| xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $444 | ― | 10.10% | Reiterated | ||||
 | GXO Logistics | BUY $66 | ― | -1.60% | Reiterated | GXO Logistics (GXO) Gets a Buy from Stifel Nicolaus | |||
| xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $559 | ― | 0.60% | Reiterated | ||||
| xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $18 | ― | 3.50% | Upgraded | ||||
 xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $450→$430 | ― | 13.00% | Reiterated | ||||
| xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $390→$370 | ― | 1.00% | Reiterated | ||||
| xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $215→$210 | ― | 1.00% | Reiterated | ||||
| xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $210→$203 | ― | 13.00% | Reiterated | ||||
 | Procter & Gamble | BUY $181→$172 | ― | -0.40% | Reiterated | Procter & Gamble price target lowered to $172 from $181 at JPMorgan | |||
| Clorox | HOLD $173→$151 | ― | -0.40% | Reiterated | Clorox price target lowered to $151 from $173 at JPMorgan | |||
| Kimberly Clark | SELL $124→$131 | ― | -0.40% | Reiterated | Kimberly-Clark price target raised to $131 from $124 at JPMorgan | |||
| Church & Dwight | SELL $106→$98 | ― | -0.40% | Reiterated | Church & Dwight price target lowered to $98 from $106 at JPMorgan | |||
| SharkNinja, Inc. | BUY $139→$98 | ― | -0.40% | Reiterated | SharkNinja price target lowered to $98 from $139 at JPMorgan | |||
| Colgate-Palmolive | BUY $99→$95 | ― | -0.40% | Reiterated | Colgate-Palmolive price target lowered to $95 from $99 at JPMorgan | |||
| e.l.f. Beauty | BUY $127→$70 | ― | -0.40% | Reiterated | Elf Beauty price target lowered to $70 from $127 at JPMorgan | |||
| The Estée Lauder Companies | HOLD $72→$61 | ― | -0.40% | Reiterated | Estee Lauder price target lowered to $61 from $72 at JPMorgan |
Rows:
